Related Experiment Video

Updated: Aug 24, 2026

Probiotic Studies in Neonatal Mice Using Gavage
10:36

Probiotic Studies in Neonatal Mice Using Gavage

Published on: January 27, 2019

Management of infant diarrhea with high-lactose probiotic-containing formula

Subijanto Marto Sudarmo1, Reza G Ranuh, Abdul Rochim

  • 1Airlangga University School of Medicine--Dr Soetomo Hospital, Gastroenterology Division, Department of Child Health, Surabaya, Indonesia.

The Southeast Asian Journal of Tropical Medicine and Public Health
|April 30, 2004
PubMed

Insights

High-lactose probiotic formula did not significantly alter overall recovery from acute diarrhea. However, it did lead to a reduced frequency of stools in patients compared to the control group.

Area of Science:

  • Gastroenterology
  • Microbiology
  • Pediatrics

Background:

  • Acute diarrhea remains a significant health concern, particularly in pediatric populations.
  • Probiotics are increasingly explored for their potential to modulate gut health and influence the course of infectious diarrhea.
  • The role of specific probiotic strains and their formulations, such as high-lactose Bifidobacterium bifidum, warrants further investigation.

Purpose of the Study:

  • To evaluate the efficacy of a high-lactose probiotic-containing formula in managing acute diarrhea.
  • To compare the clinical outcomes, including stool frequency and recovery rates, between patients receiving the probiotic formula and a control group.

Main Methods:

  • A randomized controlled clinical trial was conducted with 100 patients experiencing acute diarrhea.
  • Patients were divided into two groups: one received a high-lactose Bifidobacterium bifidum formula, while the control group did not receive the probiotic.
  • Outcomes were assessed by monitoring diarrhea duration, stool frequency, and recovery, with statistical analysis using chi-square and Fisher exact tests (alpha=0.05).

Main Results:

  • No statistically significant differences were observed between the groups regarding overall clinical test outcomes (13%) or positive floating test results (65%).
  • Patients administered the high-lactose probiotic-containing formula exhibited a significantly lower frequency of stools compared to the control group (p<0.05).

Conclusions:

  • While high-lactose Bifidobacterium bifidum formula did not significantly impact overall recovery from acute diarrhea, it demonstrated a beneficial effect in reducing stool frequency.
  • Further research may explore the specific mechanisms by which this probiotic formulation influences intestinal transit time and stool characteristics in acute diarrhea.

More Related Videos

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods08:38

Novel Production Protocol for Small-scale Manufacture of Probiotic Fermented Foods

Published on: September 10, 2016

Related Concept Videos

Development of Human Microbiota01:30

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...